Ajanta Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

19.09×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.64×	2.64×	2.84×	3.04×	2.48×
1.98×	1.98×	1.93×	2.12×	1.76×
663	663	614	460	840
2,320	2,320	1,834	1,827	1,686

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.70

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,367 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	19.09
Current Ratio	2.48	3.04	2.84	2.64	2.64
Quick Ratio	1.76	2.12	1.93	1.98	1.98
Cash, Equiv & ST Investments	840.1	459.5	613.8	663.1	663.1
Working Capital	1,685.9	1,826.8	1,833.6	2,319.7	2,319.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.